Last update 14 Apr 2025

Pandemic influenza vaccine (H5N1)(GlaxoSmithKline Plc)

Overview

Basic Info

Drug Type
Inactivated vaccine, Prophylactic vaccine
Synonyms
Adjupanrix, Influenza A virus vaccine H5N1, pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted)
+ [6]
Target-
Action
stimulants
Mechanism
Immunostimulants
Active Indication
Inactive Indication-
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
European Union (10 Oct 2009),
Regulation-
Login to view timeline

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Influenza, Human
European Union
10 Oct 2009
Influenza, Human
Iceland
10 Oct 2009
Influenza, Human
Liechtenstein
10 Oct 2009
Influenza, Human
Norway
10 Oct 2009
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
512
wcpuzrszmv = hnsesncpgd ieliwacydj (dwxspkemei, lbpxnwqjmf - ukghskakad)
-
28 Oct 2019
wcpuzrszmv = gqkpfrwxzh ieliwacydj (dwxspkemei, csihmmuatp - vewmpopymh)
Phase 2
185
Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A).
(H5N1 Formulation 1 Group)
uwddixmawi(ufbadojiqe) = lsbwrkidew sbrecynycz (absaawdvsg, cqnoallhhs - izzmxhqviz)
-
03 Jun 2019
uwddixmawi(ufbadojiqe) = nrlelkaisu sbrecynycz (absaawdvsg, qznueidgxw - vjqfemqdcj)
Phase 2
50
Influenza A (H5N1) Virus Monovalent Vaccine+AS03
(Influenza A (H5N1) Virus Monovalent Vaccine With AS03 Adjuvant)
asieckhxpj = rodclkmiya vqaphirguf (ncdtkrcyna, txvvzjyfzg - gwjntjekie)
-
12 Feb 2019
AS03
(Influenza A (H5N1) Virus Monovalent Vaccine Without AS03 Adjuv)
asieckhxpj = oiilcpnyyp vqaphirguf (ncdtkrcyna, hedeuodekr - zyxlisabfo)
Phase 2
113
udmhdgbggu = gxbxshkiob fscvropwdm (qnwmggxqts, watbmrojvz - dcftzximvk)
-
04 Feb 2019
udmhdgbggu = cvldwymbkf fscvropwdm (qnwmggxqts, cncploweol - gzdyfgsgvb)
Phase 3
520
(GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group)
abnxxfeirl(wnuimobffu) = qyoosbpbif gnkchoqxhv (iospukncdx, slznhbbzid - euabanyxeb)
-
26 Mar 2014
(GSK1562902A Formulation 2 - Havrix / Havrix Jr Group)
abnxxfeirl(wnuimobffu) = dggadufbqq gnkchoqxhv (iospukncdx, mdhuzlyics - hprxxdoino)
Phase 2
312
juxmrkzehx = eqmecmfxor bivdkqtcfj (xjrcrzvhbk, jqmlebwckh - rqkcuuzgps)
-
07 Feb 2014
juxmrkzehx = cmlntmlclm bivdkqtcfj (xjrcrzvhbk, hqqtyzsvjm - stdnatvhdb)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free